These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35865463)

  • 1. Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing
    Varughese LA; Bhupathiraju M; Hoffecker G; Terek S; Harr M; Hakonarson H; Cambareri C; Marini J; Landgraf J; Chen J; Kanter G; Lau-Min KS; Massa RC; Damjanov N; Reddy NJ; Oyer RA; Teitelbaum UR; Tuteja S
    Front Oncol; 2022; 12():859846. PubMed ID: 35865463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation.
    Lau-Min KS; Varughese LA; Nelson MN; Cambareri C; Reddy NJ; Oyer RA; Teitelbaum UR; Tuteja S
    BMC Cancer; 2022 Jan; 22(1):47. PubMed ID: 34996412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.
    Reizine N; Vokes EE; Liu P; Truong TM; Nanda R; Fleming GF; Catenacci DVT; Pearson AT; Parsad S; Danahey K; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
    Ther Adv Med Oncol; 2020; 12():1758835920974118. PubMed ID: 33414846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.
    Varughese LA; Lau-Min KS; Cambareri C; Damjanov N; Massa R; Reddy N; Oyer R; Teitelbaum U; Tuteja S
    Pharmacotherapy; 2020 Nov; 40(11):1108-1129. PubMed ID: 32985005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists.
    Glewis S; Lingaratnam S; Krishnasamy M; H Martin J; Tie J; Alexander M; Michael M
    J Oncol Pharm Pract; 2024 Jan; 30(1):30-37. PubMed ID: 37021580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey.
    Glewis S; Krishnasamy M; Lingaratnam S; Harris S; Underhill C; Georgiou C; Warren M; Campbell R; IJzerman M; Fagery M; Campbell I; Martin JH; Tie J; Alexander M; Michael M
    Clin Transl Sci; 2023 Dec; 16(12):2700-2708. PubMed ID: 37877594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study.
    Fragoulakis V; Roncato R; Bignucolo A; Patrinos GP; Toffoli G; Cecchin E; Mitropoulou C
    Pharmacol Res; 2023 Nov; 197():106949. PubMed ID: 37802427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of a pharmacogenetic panel-based test for pharmacotherapy-based supportive care in an adult oncology clinic.
    Cicali EJ; Eddy E; Gong Y; Elchynski AL; Pena Del Aguila K; Basha T; Daily KC; Dickson L; Fischer S; Hastings-Monari E; Jones D; Ramnaraign BH; DeRemer DL; George TJ; Cooper-DeHoff RM
    Clin Transl Sci; 2024 Jul; 17(7):e13890. PubMed ID: 39046302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting.
    Luczak TS; Schillo PJ; Renier CM; Waring SC; Friday BB
    J Oncol Pharm Pract; 2022 Jun; 28(4):842-849. PubMed ID: 33853470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
    Morris SA; Moore DC; Musselwhite LW; Lopes KE; Hamilton A; Steuerwald N; Hanson SL; Larck C; Swift K; Smith M; Kadakia KC; Chai S; Hwang JJ; Patel JN
    Am J Health Syst Pharm; 2023 Sep; 80(19):1342-1349. PubMed ID: 37235983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
    Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
    BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository.
    Pasternak AL; Seda R; Lipa J; McDevitt RL; Crysler OV; Swiecicki PL; Schneider BJ; Vanderwerff B; Henry NL; Krauss JC; Sahai V; Hertz DL
    Clin Pharmacol Ther; 2023 Aug; 114(2):356-361. PubMed ID: 37163252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary care and mental health providers' perceptions of implementation of pharmacogenetics testing for depression prescribing.
    Vest BM; Wray LO; Brady LA; Thase ME; Beehler GP; Chapman SR; Hull LE; Oslin DW
    BMC Psychiatry; 2020 Oct; 20(1):518. PubMed ID: 33115428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial.
    Oslin DW; Chapman S; Duvall SL; Gelernter J; Ingram EP; Kranzler HR; Lehmann LS; Lynch JA; Lynch KG; Pyne JM; Shih MC; Stone A; Thase ME; Wray LO
    Contemp Clin Trials; 2021 Feb; 101():106247. PubMed ID: 33316457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients:
    Ragia G; Maslarinou A; Atzemian N; Biziota E; Koukaki T; Ioannou C; Balgkouranidou I; Kolios G; Kakolyris S; Xenidis N; Amarantidis K; Manolopoulos VG
    Front Pharmacol; 2023; 14():1248898. PubMed ID: 37781702
    [No Abstract]   [Full Text] [Related]  

  • 17. Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial.
    Hassett MJ; Wong S; Osarogiagbon RU; Bian J; Dizon DS; Jenkins HH; Uno H; Cronin C; Schrag D;
    Trials; 2022 Jun; 23(1):506. PubMed ID: 35710449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature.
    Conti V; De Bellis E; Manzo V; Sabbatino F; Iannello F; Dal Piaz F; Izzo V; Charlier B; Stefanelli B; Torsiello M; Iannaccone T; Coglianese A; Colucci F; Pepe S; Filippelli A
    J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32899374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review.
    B Tata E; A Ambele M; S Pepper M
    Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32858798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
    Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
    Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.